PatientsVille.com Logo

BLOOD CALCIUM DECREASED and RECLAST

PatientsVille

BLOOD CALCIUM DECREASED Symptoms and Causes

Electrolytes are minerals in your body that have an electric charge. They are in your blood, urine, tissues, and other body fluids. Electrolytes are important because they help

  • Balance the amount of water in your body
  • Balance your body's acid/base (pH) level
  • Move nutrients into your cells
  • Move wastes out of your cells
  • Make sure that your nerves, muscles, the heart, and the brain work the way they should

Sodium, calcium, potassium, chlorine, phosphate, and magnesium are all electrolytes. You get them from the foods you eat and the fluids you drink.

The levels of electrolytes in your body can become too low or too high. This can happen when the amount of water in your body changes. The amount of water that you take in should equal the amount you lose. If something upsets this balance, you may have too little water (dehydration) or too much water (overhydration). Some medicines, vomiting, diarrhea, sweating, and liver or kidney problems can all upset your water balance.

Treatment helps you to manage the imbalance. It also involves identifying and treating what caused the imbalance.

Check out the latest treatments for BLOOD CALCIUM DECREASED

BLOOD CALCIUM DECREASED treatment research studies

RECLAST clinical trials, surveys and public health registries


Find Drug Side Effect reports



RECLAST Side Effects

Arthralgia (599)
Pain (418)
Myalgia (402)
Headache (341)
Bone Pain (334)
Pyrexia (332)
Influenza Like Illness (315)
Nausea (272)
Chills (241)
Asthenia (234)
Fatigue (233)
Back Pain (228)
Pain In Extremity (213)
Dizziness (181)
Dyspnoea (177)
Chest Pain (163)
Vomiting (163)
Malaise (141)
Gait Disturbance (136)
Diarrhoea (128)
Death (122)
Pain In Jaw (121)
Muscle Spasms (112)
Feeling Abnormal (101)
Abasia (99)
Musculoskeletal Pain (99)
Oedema Peripheral (98)
Blood Creatinine Increased (95)
Fall (89)
Joint Swelling (84)
Neck Pain (83)
Dehydration (79)
Confusional State (76)
Muscular Weakness (73)
Blood Pressure Increased (69)
Abdominal Pain (67)
Renal Failure Acute (67)
Musculoskeletal Stiffness (66)
Paraesthesia (66)
Hypoaesthesia (65)
Decreased Appetite (63)
Insomnia (60)
Erythema (59)
Eye Pain (58)
Chest Discomfort (57)
Atrial Fibrillation (56)
Activities Of Daily Living Impaired (55)
Hypocalcaemia (54)
Syncope (53)
Osteonecrosis (52)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I just had the infusion two days ago (1/19/10) and was surprised with the intensity of muscle pain the day after the treatment. My pain was localized to my rib cage, neck, shoulders and upper back. In addition I was very fatiqued...slept most of

"Association does not equal causation": posters seem to assume that any symptom occurring within a year of the Reclast infusion is caused by Reclast (just noticing that, and wondering whether the manufacturer needs to do a better jo

<span style='color: #808080;'>i was very unsure about reclast but the specialist was very pushie about me tring it,when i read up on it everything negative ( as far as reviews) my doc said don't go by reviews.aftre 2 mths i

Tell women not to take this drug. I for see huge lawsuits in the future. I may not live that long but it will happen! I was told to report to the hospital for my infusion. No one told me mu

<span style='color: #808080;'>si vous prenez le medrol 16 mg mangez des dattes et des bananes qui sont riches en potassium et n'oubliez pas de faire des analyses de temps en temps , une chute de potassium pourrait&ecirc;tre&nb

<strong></strong><span style='color: #808080;'>I had my first Reclast infusion last Thursday morning. I am a nurse so am on my feet a lot and at work Thursday evening I started having pain across the back of my

12 hours after Reclast IV, had fever, chills, pain in stomach, dizziness, headache - lasted 12 hours on and off - scary.

2 months after injection . I want to say I was extremely ill the day, about 10 hours afterwards , I got my Iv infusion of this medication . About 10 hours after the IV infusion I became very sick , Flu like symptoms , 103.6 temperture , thought

About 6 weeks after I got Reclast I got pains in my groin and hip. Is that a coincidence or is it possible to have these symptoms so long after the infusions. It is now 5 months and I now have pain in both hips, back and tingling in my feet and one

After my first (and last) experience with this drug, on January 5, 2011, I'm in pain. My back,my shoulder, my neck, my chest hurt. I'm taking pain killers to deal with the pain, but its not enough. Did someone had a better way ease the pain?

Calculate the moles of calcium carbonate present in a 25.00 mL sample of a standard solution, assuming the standard is known to have a hardness of 105 ppm (hardness due to CaCO3 ). You can assume that the density

I've been taking Coversyl for almost two weeks now. My doctor prescribed it when the Natrilix I had been taking for a couple of months wasn't bringing my blood pressure down fast enough. The only side effects I've noticed since commencing the C

Does panadeine increase blood pressure?

I HAD 1 SHOT OF THIS AND WITHIN 12 HOURS I WENT FROM A VERY NORMAL BLOOD PRESSURE TO WAKING AT 5 A.M. NEXT DAY WITH 198/110 AND 104 PULSE RATE. IT HAS CONTINUED ALL WEEK AFTER AND I'M NOW ON A BLOOD PRESSURE DRUG TO TRY AND CONTROL IT. EVEN WITH DR

I have just come back from a funeral for my brother. He was just 62. He was on statin medicine but his cholestrol, blood pressure, weight and diet was very much in control. In fact just a day before his death the doctor told him that he was doing f

Since taking Karvezide (2years after Karvea was proved to unsuccessfull in reducing my high blood pressusre) I have experienced a lot of problems with nasal drip and a permanent muscas build up in the throat. Nothing seems to relieve the problem.

When I reported to my doctor that i was frequently having to urinate he had a blood test carried out with the result that my prostrate was OK he prescribed Permixon 160 mg twice per day and Tamsulosina STADA 0,4 mg once per day. I am now urinating

Can your body assimilate calcium with out magnesium????

fell dizziness and was admitted. Doc execute with dianostic including blood teat and heart check all. good. Doc make a decision by saying i'm getting Vertigo and treat with BETASERC. Below is the effect after 2 days take this medicine:- I was

I have an ear infection where my ear canal is covered in blisters and blood/fluid coming out, also mu ear is completely blocked. I am on antibiotics and drops but a friend mentioned that they took oflocet 200mg when had a similar problem, but I hav

BLOOD CALCIUM DECREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting The Use of Zoledronic Acid to Complex Regional Pain Syndrome
Condition: Complex Regional Pain Syndromes
Interventions: Drug: Zoledronic acid;   Drug: Placebo
Outcome Measures: Pain measured on Visual Analog Scale;   Lower Limbs vertical force on Wii platform;   American Orthopaedic Foot and Ankle Scale (AOFAS);   36-Item Short Form Health Survey (SF-36)
2 Recruiting Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
Condition: Mesothelioma
Intervention: Drug: Zometa (zoledronic acid)
Outcome Measures: Evaluation of the tumor response rate following zoledronic acid;   Evaluation of the duration of tumor response
3 Recruiting Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Drug: zoledronic acid;   Other: laboratory biomarker analysis;   Procedure: therapeutic conventional surgery
Outcome Measures: Changes in biomarkers of tumor growth and metastasis in women with newly diagnosed ER and/or PR positive invasive ductal breast cancer receiving zoledronic acid;   Changes in immunologic function after a single dose of zoledronic acid;   Changes in the expression of tumor markers important to breast cancer progression and metastasis in women receiving zoledronic acid
4 Recruiting Zoledronic Acid in Acute Spinal Cord Injury
Condition: Complete Traumatic Spinal Cord Injury
Interventions: Drug: Zoledronic acid;   Drug: normal saline 0.9%
Outcome Measures: change in bone mineral density;   Biomarkers of bone formation and resorption;   safety and tolerability of zoledronic acid
5 Unknown  Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma
Condition: Osteosarcoma
Interventions: Drug: Zoledronic acid;   Drug: Standard chemotherapy
Outcome Measure: histological response disease free interval
6 Recruiting The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
Condition: Osteogenesis Imperfecta
Interventions: Drug: Zoledronic acid;   Drug: Teriparatide;   Drug: placebo zoledronic acid;   Drug: placebo teriparatide
Outcome Measures: Bone Mineral Density (BMD);   Fracture risk
7 Recruiting Bone Loss Treatment From Adjuvant Zoledronate Efficacy
Conditions: Breast Neoplasms;   Bone Loss
Intervention: Drug: Zoledronate
Outcome Measures: Change from Baseline in Bone Mineral Density;   Bone metastasis rate;   Disease-Free Survival
8 Recruiting Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Conditions: Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab;   Drug: Zoledronic acid
Outcome Measures: Time to the first on-study skeletal related event (SRE) (non-inferiority test);   Time to the first-and-subsequent SRE (superiority test, using multiple event analysis);   Time to the first on-study SRE (superiority test)
9 Recruiting Effect of the Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Who Have Relapsed After 1-3 Prior Lines of Therapy
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Zoledronic Acid;   Drug: Dexamethasone
Outcome Measures: Bone Mineral Density (BMD);   Bone mineral density (BMD);   Serum values of bone-specific alkaline phosphatase, osteocalcin and C-terminal cross-linking telopeptides of collagen type-I;   Bone pain;   Skeletal-related events (SRE: pathologic fractures, need for bone radiation therapy or surgery);   Improvement of osteolytic lesions
10 Not yet recruiting Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid
Conditions: Malignant Neoplasm;   Musculoskeletal Complications
Interventions: Drug: zoledronic acid;   Other: pharmacological study
Outcome Measures: Plasma concentrations of Zol collected at visits 2, 3, 4, and 5;   Urine concentrations of Zol collected at visits 2, 3, 4, and 5;   Jawbone tissue concentrations of Zol collected during surgical treatment for BRONJ;   Identify potential risk factors for BRONJ
11 Recruiting Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Zoledronic Acid;   Biological: Aldesleukin
Outcome Measures: Evaluate the safety and toxicity of zoledronic acid and aldesleukin;   Evaluate the biologic function of autologous expanded/activated gamma delta T cells in neuroblastoma patients receiving therapy with zoledronic acid and aldesleukin;   uoEvaluate immune phenotype of in vivo expanded/activated autologous gamma delta T cells;   To document tumor response in patients with measurable disease.;   Determine the ability of in vivo expanded/activated gamma delta T cells to infiltrate neuroblastoma tissue using immunohistochemical techniques when post-therapy specimens are available.
12 Recruiting The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Pamidronate;   Drug: Zoledronic acid;   Drug: placebo
Outcome Measures: sCTX values;   Palliative response
13 Recruiting Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)
Conditions: Giant Cell Tumor of Bone;   Osteoclastoma
Intervention: Drug: Zoledronic acid
Outcome Measures: Determine if adjuvant zoledronic acid improves the 2 year recurrence rate of 'high risk' GCT as compared to standard care;   Evaluate the usefulness of bone remodelling markers in diagnosing and monitoring GCT;   Determine the relapse free survival
14 Recruiting N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Bevacizumab;   Drug: cyclophosphamide;   Drug: zoledronic acid
Outcome Measures: Determination of toxicities and feasibility of the combination of bolus plus metronomic cyclophosphamide and zoledronic acid with and without bevacizumab when given to children with refractory or recurrent high risk neuroblastoma.;   Evaluation of response within the confines of a phase I study.;   Analysis of Circulating Endothelial Cells, Circulating Factors, Gene expression and Bone Metabolism Studies.
15 Recruiting FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)
Condition: Osteoporosis
Interventions: Other: FES-Rowing;   Drug: Zoledronic acid
Outcome Measures: Improvement of bone mass as measured by sequential evaluation of bone density and bone structure;   Validation of DXA Scanning in patients with SCI
16 Recruiting 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Condition: Osteoporosis
Intervention: Drug: zoledronic acid
Outcome Measures: Safety of zoledronic acid for the treatment of osteoporotic children treated with glucocorticoids for chronic inflammatory conditions by adverse event collection and laboratory results monitoring.;   Change from baseline in LS areal BMD Z-score at Month 18 and 24 by core treatment group by dual energy x-ray absorptiometry (DXA).;   Change from baseline in LS and total body BMC by core treatment group by DXA.;   Change in biochemical marker values (serum P1NP, BSAP, NTx and TRAP-5b) from baseline.;   Change in the number of new clinical vertebral fractures and new morphometric vertebral fractures.;   To evaluate the change from baseline (Visit 1 of the Core study) in pain using the Faces Pain Scale-Revised (FPS-R)by core treatment group.
17 Unknown  Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
Condition: Hepatocellular Carcinoma
Intervention: Drug: Sorafenib and Zoledronic Acid
Outcome Measures: numbers of adverse events;   Overall survival (OS), time to progression (TTP)
18 Recruiting Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Zoledronic Acid and Aromatase Inhibitors
Outcome Measures: therapeutic assessment;   Adverse reactions and disease-free survival
19 Recruiting HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
Condition: Breast Cancer
Interventions: Drug: tamoxifen;   Drug: triptorelin;   Drug: letrozole;   Drug: zoledronic acid
Outcome Measures: disease free survival in premenopausal patients;   bone mineral density;   Bone mineral density measured;   disease free survival in postmenopausal patients;   overall survival;   toxicity of letrozole + triptorelin and letrozole + zoledronic acid + triptorelin in premenopausal patients
20 Not yet recruiting Zoledronic Acid in Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Intervention: Drug: Zoledronic acid
Outcome Measure: Sharp van der Heijde index